Legumain在恶性肿瘤中的研究现状  

Progresses on Legumain in Malignant Tumors

作　　者：李荣[1] 胡维新[1] 

机构地区：[1]中南大学生物科学与技术学院分子生物学研究中心,中国湖南长沙410078

出　　处：《生命科学研究》2012年第2期169-171,180,共4页Life Science Research

基　　金：国家自然科学基金资助项目(30400256)

摘　　要：Legumain是一种溶酶体半胱氨酸蛋白酶,是半胱氨酸蛋白酶C13家族的新成员.研究表明,Legumain作为一种应激性蛋白,在多种实体瘤、肿瘤相关巨噬细胞(TAMs)、肿瘤新生血管的内皮细胞中高表达,与恶性肿瘤的血管生成、肿瘤侵袭、扩散和转移密切相关,是近年来备受关注的一类靶标蛋白酶.对Legumain的深入研究将有利于阐明恶性实体瘤的发病机制,明确其作为肿瘤基因治疗新靶标的有效性.The Legumain is a lysosomal proteinase belonging to a novel member of the C13 family of cys- teine proteases. Legumain, as a stress protein, has been reported to be overexpressed in the majority of hu- man solid tumors, particularly in tumor-associated macrophages （TAMs） and tumor endothelial cells. Its over- expression is believed to associated with malignant tumor invasion, proliferation and metastasis, which makes Legumain attract much attention recently, as a candidate provide us new insights into pathopaysiology processes of promising biomarker for cancer gene therapy. enzymatic target. Further studies on Legumain may solid tumors, and help us evaluate its efficacy as a

关 键 词：LEGUMAIN 恶性肿瘤 基因治疗 

分 类 号：Q74[生物学—分子生物学]